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ABSTRACT 
Infectious canine tracheobronchitis (ICT) or canine infectious respiratory disease, commonly known 
as kennel cough, is an acute, highly contagious respiratory disease that affects the larynx, trachea, 
bronchi, and occasionally the parenchyma of the lower respiratory tract. Several pathogens have 
been implicated in ICT including viruses, bacteria and mycoplamsa. Little is known about the 
prevalence of canine respiratory pathogens in New Zealand. Hence, the aim of this study was to 
identify potential respiratory pathogens from dogs that are affected by ICT in New Zealand, 
and compare agents found in diseased dogs to those found in healthy dogs. In house (IH) 
qPCR assays were  developed for the detection of canine adenovirus type 2 (CAdV-2), canine 
herpesvirus (CHV) and canine parainfluenza (CPIV).         
A total of 96 dogs were sampled, including 47 healthy and 49 diseased dogs, which 
comprised three different groups of dogs: greyhounds, pet dogs, and working farm dogs. A 
questionnaire was included for each dog sampled. The samples collected were then 
subjected to the following tests: virus isolation, haemagglutination assay for CPIV, IH qPCR 
for CAdV-2 and CHV, as well as IDEXX RealPCR respiratory disease panel, and bovine 
respiratory coronavirus ELISA to detect antibody to canine respiratory coronavirus (CRCoV). 
Based on IDEXX qPCR, CPIV (7.3%), Bordetella bronchiseptica (7.3%) and Mycoplasma cynos 
(17.0%) were the most common agents detected in samples from diseased dogs, whereas 
CAdV-2 (10.6%) was the most common pathogen amongst healthy dogs. Based on IH qPCR, 
CAdV-2 infection was very common among all dogs sampled, with 34/47 (72%) positive 
diseased dogs and 37/47 (78.6%) positive healthy dogs.  
A total of 47/92 (51%) of dogs were positive for CRCoV antibodies, including 32/46 (69.6%) 
of diseased dogs and 14/46 (30.4%) of healthy dogs. In addition, acute serum samples from 
diseased dogs were significantly more likely to be positive for CRCoV antibodies compared 
to sera from healthy dogs (RR 5.22, CI 1.972, 14.115, p=0.0003). 
The results of this study suggest that CRCoV, M.cynos and potentially CPIV may have a role 
in ICT in New Zealand, however further investigation is required to support these findings. In 
addition, if one excluded dogs positive for CAdV-2 (as there was no difference in levels of 
detection of this virus between healthy and diseased dogs), then only 13/47 (27.6%) of 
diseased dogs were positive for at least one agent via IDEXX and IH qPCR. This suggests that 
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other aetiological agents, not examined in this study, may have contributed to respiratory 
disease in sampled dogs. Techniques such as next generation sequencing may help to 
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